Amphastar Pharmaceuticals (AMPH) Stock Statistics & Valuation Metrics

Amphastar Pharmaceuticals has a market cap or net worth of $1.41B. The enterprise value is $1.53B.

Amphastar Pharmaceuticals has 46,495,075 shares outstanding. The number of shares has decreased by -2.65% in one year.

Amphastar Pharmaceuticals’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 12.28%.

The current PE Ratio of Amphastar Pharmaceuticals is 11.4. Amphastar Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Amphastar Pharmaceuticals had revenue of 712.81M and earned 159.52M in profits. Earnings per share was 3.29.

In the last 12 months, operating cash flow was 159.66M and capital expenditures -47.47M, giving a free cash flow of 112.19M billion.

Amphastar Pharmaceuticals pays an annual dividend of $0.3, resulting in a dividend yield of ―

Amphastar Pharmaceuticals upcoming earnings date is Nov 10, 2025, After Close (Confirmed).

Amphastar Pharmaceuticals as a current ratio of 3.07, with Debt / Equity ratio of 6.31%

In the past 12 months, Amphastar Pharmaceuticals has paid 29.67M in taxes.

Amphastar Pharmaceuticals EV to EBITDA ratio is 8.28, with an EV/FCF ratio of 13.33.

Amphastar Pharmaceuticals has $231.75M in cash and marketable securities with $47.77M in debt, giving a net cash position of -$183.98M billion.

Gross margin is 50.03%, with operating margin of 28.82%, and net profit margin of 22.38%.

The average price target for Amphastar Pharmaceuticals is $32.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy